Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

4 big analyst picks: Albemarle scores fresh Overweight rating

Published 2023-05-12, 06:06 a/m
Updated 2023-05-12, 06:06 a/m

By Davit Kirakosyan

Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades for Albemarle, Euronav, Arcturus Therapeutics, and Palo Alto Networks.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Albemarle shares gain on KeyBanc upgrade

KeyBanc upgraded Albemarle (NYSE:ALB) to Overweight from Sector Weight with a price target of $270, as reported in real time on InvestingPro. The firm cited attractive valuation and improving risk-reward in lithium due to developments in China. As a result, shares gained more than 2% yesterday and are currently trading 1% higher in pre-market.

KeyBanc expects demand for lithium in China to improve after a downturn that started in November 2022, noting that its recent checks from the Li industry in China indicate that inventories at the battery cell/EV OEM level are declining, and could bottom out in the coming months.

Earlier this month, the company reported its Q1 results, beating EPS estimates while missing on revenues.

InvestingPro | Always Know First

Euronav upgraded to Buy after Q1 beat

Deutsche Bank upgraded Euronav (NYSE:EURN) to Buy from Hold with a price target of $20.00, noting there are some short-term macroeconomic and demand headwinds that still overhang the segment, but the medium-term outlook remains generally positive based on very constrained net fleet growth in the coming years.

Share gained more than 5% yesterday after the company reported better-than-expected Q1 earnings.

According to Deutsche Bank, the company is well-positioned to take advantage of an improving market.

2 more analyst picks

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

H.C. Wainwright upgraded Arcturus Therapeutics (NASDAQ:ARCT) to Buy from Neutral with a price target of $51.00, noting that the company is poised to transform into a commercial-stage company given the expected ARCT-154 approval in Japan as COVID-19 vaccine and booster in 2023.

Shares surged more than 10% yesterday.

CapitalOne initiated coverage on Palo Alto Networks (NASDAQ:PANW) with an Overweight rating.

The company is set to report its Q3/23 earnings on May 23.

Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.